open access

Vol 17, No 3 (2013)
Artykuły redakcyjne
Published online: 2013-09-09
Get Citation

Do sartans reduce the risk of cognitive impairment in the course of hypertension?

Jerzy Głuszek, Anna Wolska-Bułach
Nadciśnienie tętnicze 2013;17(3):203-211.

open access

Vol 17, No 3 (2013)
Artykuły redakcyjne
Published online: 2013-09-09

Abstract

Long term, particularly uncontrolled hypertension causescognitive impairment. The results of recent meta-analyzeson the effects of antihypertensive drug therapy on the inhibitionof cognitive impairment are different. In some ofthem there was a small, but significant reduction in the riskof developing dementia, other did not confirm the beneficialeffect of these drugs. In 2004, Fournier hypothesizedthat some antihypertensive drugs have properties inhibitthe growth of cognitive impairment in patients with hypertension.These include calcium channel blockers, particularlysartans, that work by AT2 and AT4 receptors located inthe brain tissue. Our study discusses the number of experimentalresearches in animals and in vitro studies, whichindirectly confirm a significant positive influence sartans toreduce the risk of dementia in patients with hypertension.These drugs improve the cerebral blood flow, reduced inpatients with impaired cognitive ability, have anti-inflammatoryeffect and reduce oxidative stress in brain tissue,and may also inhibit the deposition of beta-amyloid inthe central nervous system. Clinical studies on this issueare still few. However, both epidemiological observationsand relatively small observational studies indicate to thebenefits of sartans in order to reduce the risk of dementiain patients with hypertension. This year was published meta-analysis of Marpillat et al, which showed that in patientswith uncomplicated hypertension only sartans (and up to40%) reduce the risk of developing cognitive impairment.The current observations support the original hypothesisof Fournier and now sartans therapy gives hopes fora more effective prevention of dementia in patients withhypertension.

Abstract

Long term, particularly uncontrolled hypertension causescognitive impairment. The results of recent meta-analyzeson the effects of antihypertensive drug therapy on the inhibitionof cognitive impairment are different. In some ofthem there was a small, but significant reduction in the riskof developing dementia, other did not confirm the beneficialeffect of these drugs. In 2004, Fournier hypothesizedthat some antihypertensive drugs have properties inhibitthe growth of cognitive impairment in patients with hypertension.These include calcium channel blockers, particularlysartans, that work by AT2 and AT4 receptors located inthe brain tissue. Our study discusses the number of experimentalresearches in animals and in vitro studies, whichindirectly confirm a significant positive influence sartans toreduce the risk of dementia in patients with hypertension.These drugs improve the cerebral blood flow, reduced inpatients with impaired cognitive ability, have anti-inflammatoryeffect and reduce oxidative stress in brain tissue,and may also inhibit the deposition of beta-amyloid inthe central nervous system. Clinical studies on this issueare still few. However, both epidemiological observationsand relatively small observational studies indicate to thebenefits of sartans in order to reduce the risk of dementiain patients with hypertension. This year was published meta-analysis of Marpillat et al, which showed that in patientswith uncomplicated hypertension only sartans (and up to40%) reduce the risk of developing cognitive impairment.The current observations support the original hypothesisof Fournier and now sartans therapy gives hopes fora more effective prevention of dementia in patients withhypertension.
Get Citation

Keywords

hypertension, sartans, cognitive impairment, AT2 and AT4 receptors

About this article
Title

Do sartans reduce the risk of cognitive impairment in the course of hypertension?

Journal

Arterial Hypertension

Issue

Vol 17, No 3 (2013)

Pages

203-211

Published online

2013-09-09

Bibliographic record

Nadciśnienie tętnicze 2013;17(3):203-211.

Keywords

hypertension
sartans
cognitive impairment
AT2 and AT4 receptors

Authors

Jerzy Głuszek
Anna Wolska-Bułach

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl